Keywords: Kidney, Treatment Response, ADPKD
Motivation: Traditional TKV measurement methods for assessing tolvaptan response in ADPKD are variable and limits accurate identification of responders. Reliable, reproducible tools are essential to identify patients likely to benefit from tolvaptan.
Goal(s): A reproducible MRI technique tracks ht-TKV growth and identifies predictive markers for tolvaptan responders.
Approach: A retrospective analysis of 36 ADPKD patients used MRI with deep-learning segmentation to measure ht-TKV growth before and during tolvaptan use and incorporated demographics, urine osmolality, and spleen volume.
Results: Tolvaptan reduced ht-TKV growth in over half the patients, with responders mostly male and having higher pre-treatment urine osmolality, thus emphasizing MRI's utility in individual assessment.
Impact: MRI-based ht-TKV measurements and serum urine osmolality can now be used to more accurately assess individual responses to tolvaptan in ADPKD. This enables radiologists and nephrologists to tailor treatments by identifying those most likely to benefit from therapy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords